In July, we wrote to you to urge you you to cover all PrEP medications and services without cost-sharing, and not to employ prior authorization for the purpose of steering employees to one PrEP drug or another, as is required of all non-grandfathered commercial insurance plans in the United States. On August 23, 2025, you replied, assuring us that the enrollee notice we had brought to your attention had been “sent inadvertently,” and that Delta would “cover all three formulations of PrEP without cost-sharing subject to the terms and conditions of the plans.” Unfortunately, we now have learned that Delta Air Lines intends to impose prior authorization requirements to steer employees and their family members who use PrEP to the generic formulation of PrEP effective October 1, 2025.
HIV Groups letter to CVS Health on not covering Yeztugo
We, the undersigned 64 organizations, on behalf of people and communities affected by HIV, their care providers, public health practitioners, and community-based organizations, write in response to statements made by CVS Health to the media that it does not intend to cover Yeztugo (lenacapavir), a twice-yearly long-acting injectable drug recently approved by the FDA as pre-exposure prophylaxis (PrEP) for the prevention of HIV.[1] We urge you to reconsider this decision and cover Yeztugo without delay.
Testimony to Massachusetts Joint Committee on Financial Services on Bills to Address Barriers to HIV Medication
On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of H.1245/S.717: An Act to address barriers to HIV prevention medication. PrEP is a key component of both Massachusetts and federal strategies to end the HIV epidemic. But thirteen years after the introduction of PrEP, only a third of those who would benefit from PrEP are on it, with stark racial, ethnic, and gender disparities in uptake.
Letter to NY State Assembly Insurance Comm. opposing bills to permit copay maximizers
While we share your commitment to addressing the high cost of prescription drugs, we strongly oppose A8136, legislation that would explicitly authorize the use of copay maximizer programs in New York’s health insurance market.
Letter to Employment Benefits Security Administration on Delta Air Lines employee insurance coverage of PrEP
We urge you to investigate Delta Air Lines, which is failing to cover HIV Pre-Exposure Prophylaxis (PrEP) medications in some or all of its employee health plans, as required by law. Included as part of this complaint is an image of a notice sent to an enrollee indicating that Descovy, a daily oral PrEP drug, will no longer be covered by Delta’s health insurance plan beginning on August 1, 2025. This change affects all enrollees (employees and their family members).